Skip to content
‹ Back to IndustriesHealthcare

What Should Building Managers Do If COVID Doesn’t Go Away?

We all want the coronavirus to go away and for COVID-19, social distancing and everything that goes with it to be remembered as a horrible part of a weird year. There are some encouraging signs, with Pfizer announcing promising news about a vaccine candidate and other medical companies making progress. But what if the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
What Should Building Managers Do If COVID Doesn’t Go Away?

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

We all want the coronavirus to go away and for COVID-19, social distancing and everything that goes with it to be remembered as a horrible part of a weird year.

There are some encouraging signs, with Pfizer announcing promising news about a vaccine candidate and other medical companies making progress. But what if the vaccine isn’t effective, the virus mutates or it returns in different forms, like the flu?

Those possibilities are why everyone, but especially building managers, must ask the question of what we do if COVID doesn’t go away, said John Shanahan, President of Ionogen.

“Maybe it’s a mutation or maybe the flu gets smarter. We have to have more long-term strategies for getting people back into business,” Shanahan said.

Shanahan has found his company’s hypochlorous solutions highly effective in Ionogen’s own office, with none of his team of 50 testing positive for COVID during the pandemic.

“In February, when this really started to ramp up, we deployed all the humidification devices in our building. Because we made surface sanitizers and disinfectants and they were still trying to figure out what COVID was, we put the air sanitizers up as a preventative measure,” he said. “We were so busy February, March, April and May that there was no stopping. But because we have both the physical staff in our manufacturing division and we needed to be able to collaborate, we just added more units into our space.”

Now, they’re looking into the positive results of hypochlorous actually getting into the upper respiratory areas and potentially killing the virus.

“We’re very excited about the future of where this is going to take us. We will continue, as always, to do more testing and trials and the continued research on this,” Shanahan said. “We’re committed to science, and we like proof. Anecdotes are great, and we’ve got a lot of anecdotes about how this has worked up until now. Now, we’ll continue to dig down into the science. Hypochlorous could very well be the antidote without having to take the immunization.”

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Bon Secours Mercy Health agrees to buy surgery center chain Surgery Partners for $5.7 billion

Bon Secours Mercy Health agrees to buy surgery center chain Surgery Partners for $5.7 billion

Bon Secours Mercy Health affiliate HealthSpan Partners agreed to acquire Surgery Partners in a $5.7 billion deal. The chain reported $3.31 billion in revenue during 2025, according to Fierce Healthcare. Insurers in its 30 states may face a bigger negotiator.

  • 01Surgery Partners reported $3.31 billion in revenue for 2025, while Bon Secours Mercy Health reported just under $14 billion, according to Fierce Healthcare. That suggests outpatient surgery could become a major part of the system's business.
  • 02After the expected Q1 2027 close, watch insurer renewals covering both Bon Secours hospitals and Surgery Partners centers in its 30-state footprint.

Nov 2, 2026

Why CAHPS still swings Star Ratings at half its old weight

Why CAHPS still swings Star Ratings at half its old weight

mPulse’s Sam Oliver and Reva Sheehan said the CAHPS chapter moved with overall Medicare Advantage Star Ratings from 2026 to 2027 after CMS cut its weight from 4 to 2. With 11 administrative measures set to start leaving with the 2028 ratings and the equity reward cancelled, they outlined scenario planning around CAHPS, population mix and reweighting changes.

  • 01CMS cut CAHPS from a weight of 4 to 2 in the CY2025 final rule, effective with the 2026 Star Ratings, yet mPulse's chapter data shows CAHPS still moved in the same direction as overall stars for the 2027 cycle.
  • 02The April 2026 final rule removes 11 administrative measures, but none leave before the 2028 Star Ratings; the 2027 measure set is unchanged and the Health Equity Index reward is cancelled.
  • 03CAHPS stars are set by percentile cutoffs and reliability tests, and in the 2025 Star Ratings 13 percent of CAHPS results landed on a different star than the cutoff implied, 93 percent of them lower, according to RISE Health.

Nov 2, 2026

Why ECG device makers may stop rebuilding arrhythmia analysis from scratch

Why ECG device makers may stop rebuilding arrhythmia analysis from scratch

Monebo's Kinetic Software Library provides ectopic beat detection, QRS feature extraction, and heart rate and rhythm analysis for ECG devices. For ECG device engineering and regulatory teams, rhythm analysis could become a choice between building it and licensing it.

  • 01Fifty-one later FDA clearances trace their predicate lineage to Monebo's earlier libraries, a track record anyone evaluating the new one can check.

Nov 1, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512